1. Search Result
Search Result
Results for "

rhesus monkey serum

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

1

Inhibitory Antibodies

2

Natural
Products

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0890

    McN-2783-21-98

    PGE synthase Neurological Disease Inflammation/Immunology
    Zomepirac sodium salt (McN-2783-21-98) is an orally active prostaglandin synthetase inhibitor. Zomepirac sodium salt blocks prostaglandin synthesis and inhibits Collagen (HY-P72147)- or Epinephrine (HY-B0447)-induced platelet aggregation. Zomepirac sodium salt can be used for the research of postoperative pain and osteoarthritis .
    Zomepirac sodium salt
  • HY-113266
    Valerylcarnitine
    2 Publications Verification

    Endogenous Metabolite Metabolic Disease
    Valerylcarnitine is an endogenous metabolite, belonging to the short-chain acylcarnitines. Valerylcarnitine acts as a metabolomic biomarker for ionizing radiation exposure in nonhuman primates. Valerylcarnitine can be used for the research of type 1 diabetes .
    Valerylcarnitine
  • HY-113266S

    C5:0 L-carnitine-d9

    Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    Valerylcarnitine-d9 (C5:0 L-carnitine-d9) is the deuterium labeled Valerylcarnitine (HY-113266). Valerylcarnitine is an endogenous metabolite, belonging to the short-chain acylcarnitines. Valerylcarnitine acts as a metabolomic biomarker for ionizing radiation exposure in nonhuman primates. Valerylcarnitine can be used for the research of type 1 diabetes .
    Valerylcarnitine-d9
  • HY-113266R

    Reference Standards Endogenous Metabolite Metabolic Disease
    Valerylcarnitine (Standard) is the analytical standard of Valerylcarnitine. Valerylcarnitine is an endogenous metabolite, belonging to the short-chain acylcarnitines. Valerylcarnitine acts as a metabolomic biomarker for ionizing radiation exposure in nonhuman primates. Valerylcarnitine can be used for the research of type 1 diabetes .
    Valerylcarnitine (Standard)
  • HY-B0890R

    McN-2783-21-98 (Standard)

    PGE synthase Reference Standards Neurological Disease Inflammation/Immunology
    Zomepirac sodium salt (Standard) is the analytical standard of Zomepirac sodium salt (HY-B0890). This product is intended for research and analytical applications. Zomepirac sodium salt (McN-2783-21-98) is an orally active prostaglandin synthetase inhibitor. Zomepirac sodium salt blocks prostaglandin synthesis and inhibits Collagen (HY-P72147)- or Epinephrine (HY-B0447)-induced platelet aggregation. Zomepirac sodium salt can be used for the research of postoperative pain and osteoarthritis .
    Zomepirac sodium salt (Standard)
  • HY-B0890A

    McN-2783-21-98 free acid

    PGE synthase Neurological Disease Inflammation/Immunology
    Zomepirac (McN-2783-21-98 free acid) is an orally active prostaglandin synthetase inhibitor. Zomepirac blocks prostaglandin synthesis and inhibits Collagen (HY-P72147)- or Epinephrine (HY-B0447)-induced platelet aggregation. Zomepirac can be used for the research of postoperative pain and osteoarthritis .
    Zomepirac
  • HY-137357

    NSC 305986; γ-MBMTX

    Dihydrofolate reductase (DHFR) Cancer
    5-Monobutyl methotrexate (NSC 305986; γ-MBMTX) is a dihydrofolate reductase (DHFR) inhibitor and esterase substrate. 5-Monobutyl methotrexate is hydrolyzed by esterases to produce methotrexate. In rhesus monkeys, 5-Monobutyl methotrexate clears more slowly from cerebrospinal fluid than from serum, and its serum protein binding rate exceeds 99%. At the same dose rate, 5-Monobutyl methotrexate achieves cerebrospinal fluid concentrations comparable to those of Methotrexate (HY-14519), and exhibits activity against Methotrexate-resistant cells (with transport defects) that is comparable to that against sensitive parental cells. 5-Monobutyl methotrexate can be used in studies related to Methotrexate-resistant tumors .
    5-Monobutyl methotrexate
  • HY-P992463

    Ser/Thr Protease Endocrinology
    SHR-2010 is a fully humanized monoclonal antibody targeting MASP-2. SHR-2010 selectively inhibits lectin pathway activation without affecting classical or alternative complement pathways. SHR-2010 can be used for the research of IgA nephropathy .
    SHR-2010

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: